Undisclosed IRF5 inhibitor / AbbVie, HotSpot Therap - LARVOL DELTA

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting (PRNewswire) - "HotSpot's small molecule IRF5 inhibitors achieved potent, dose-dependent suppression of cytokine production in multiple human immune cell types. Additionally, in B cells, IRF5 inhibition prevented plasmablast differentiation, a key pathogenic driver in SLE; In SLE PBMCs, IRF5 inhibition demonstrated dose-dependent cytokine suppression with enhanced potency as compared to key benchmarks; In an in vivo mouse model, HotSpot's IRF5 inhibitors demonstrated dose-dependent inhibition of cytokines and mRNA response, as well as dose-dependent down-regulation of interferon and IRF5-driven gene signatures, confirming pathway-level modulation in this model."

Preclinical • Systemic Lupus Erythematosus

HotSpot Therapeutics…announced it will present preclinical data from the Company's interferon regulatory factor 5 (IRF5) program in a poster presentation at the 15th European Lupus Meeting (PRNewswire)

Preclinical • Lupus

HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025 (PRNewswire) - "HotSpot Therapeutics, Inc....today announced it will present preclinical data from the Company's interferon regulatory factor 5 (IRF5) program in an oral and poster presentation at the 25th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2025), taking place June 24-27, 2025, in Boston, MA."

Preclinical • Immunology